Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H18N2O5S |
Molecular Weight | 362.4 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)N3CCCC3
InChI
InChIKey=UJEWTUDSLQGTOA-UHFFFAOYSA-N
InChI=1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic[2] compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups. Studies of piretanide in rats and dogs in comparison with other high-ceiling diuretics such as furosemide and bumetanide found a more suitable dose/response rate (regression line) and a more favourable sodium/potassium excretion ratio. These findings led eventually to clinical studies in man and finally to the introduction as a saluretic and antihypertensive medication in Germany, France, Italy and other countries.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4051 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24117047 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Arelix Approved UseArelix is a diuretic for the management of fluid retention and treatment of mild to moderate hypertension. |
|||
Primary | Arelix Approved UseArelix is a diuretic for the management of fluid retention and treatment of mild to moderate hypertension. |
PubMed
Title | Date | PubMed |
---|---|---|
A double-blind multicentre study of piretanide and hydrochlorothiazide in patients with essential hypertension. | 1984 |
|
Drug interaction: omeprazole and phenprocoumon. | 2001 |
|
Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation. | 2005 Aug |
|
Functional characterization of human monocarboxylate transporter 6 (SLC16A5). | 2005 Dec |
|
Thiopurine S-methyltransferase as a target for drug interactions. | 2005 Jul |
|
Stability-indicating methods for the determination of piretanide in presence of the alkaline induced degradates. | 2005 Oct 4 |
Sample Use Guides
Oedema: The usual initial adult dose is 6mg daily, adjusted according to response to a maximum of 30mg. An initial dose of 3mg may be sufficient in some patients.
Hypertension: The usual initial adult dose is 6mg daily in mild to moderate hypertension. This dose should be continued for 2-4 weeks then increased if necessary at 2-4 week intervals to a maximum of 18mg daily. The maintenance dose is usually 6mg daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24117047
To investigate the voltage and external Cl− concentration dependence of channel block, we used voltage-ramp protocols to acquire current–voltage (I–V) relationships To explore the time dependence of blockade, we bathed membrane patches in symmetrical Cl−-rich solutions and stepped voltage first from 0 to −100 mV and then from −100 to +100 mV before returning to 0 mV; the duration of each voltage step was 250 ms. We averaged multiple current records (5–30) acquired in the absence and presence of drugs before subtracting basal currents with no active channels recorded in the absence of PKA (75 nM) and ATP (1 mM) to isolate macroscopic CFTR Cl− currents.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC03CA03
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
||
|
WHO-ATC |
C03CA03
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
||
|
NCI_THESAURUS |
C49184
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000081664
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
SUB09906MIG
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
55837-27-9
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
2201
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
DQ6KK6GV93
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
259-852-9
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
DTXSID2023488
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
DB02925
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
33770
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | RxNorm | ||
|
C015451
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
PIRETANIDE
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
m8875
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | Merck Index | ||
|
3741
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
CHEMBL349803
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
4849
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY | |||
|
C66419
Created by
admin on Sat Dec 16 17:29:52 UTC 2023 , Edited by admin on Sat Dec 16 17:29:52 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)